COVID-19 vaccine in up to 60,000 volunteers in an advance trial. The late-stage trial is scheduled in September, according to a report in Reuters.The trial would be conducted in nearly 180 sites across the United States and other countries, including Brazil and Mexico, according to reports."Our Phase 3 program is intended to be as robust as possible, could include up to 60,000 participants and will be conducted in places with high incidence rates," Johnson & Johnson spokesman said."We can confirm that planning and recruitment is underway for our Phase 3 program, which is subject to interim data of the Phase 1/2a trials and approval of regulators," he added.The drugmaker is using epidiological data to decide where studies should take place.